Olutasidenib with Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies

This clinical trial aims to explore the safety and effectiveness of a new treatment combination for people with certain types of blood cancers that have returned or not responded to previous treatments. These cancers have a specific genetic change called an IDH1 mutation, along with other mutations that activate certain cellular pathways. The study evaluates combining a drug called olutasidenib with other treatments, such as cladribine, LDAC, venetoclax, gilteritinib, and ruxolitinib, in patients with these mutations. The goal is to improve remission rates and survival outcomes for these patients, addressing an urgent need for better treatment options. Participants in the study receive the treatment combinations via oral or injection methods, depending on the specific drug regimen. Researchers will closely monitor patients to assess the safety and any side effects of these treatment combinations. The study measures success through various outcomes, including the rate of complete remission, overall survival, and the duration of treatment response. Additionally, the study will look at how well the cancer is reduced to undetectable levels using advanced techniques. This trial is crucial for understanding how these new drug combinations can help people with challenging forms of blood cancer.